Neurotrophic Keratitis
Conditions
Keywords
PRGF, Neurotrophic Keratitis, platelet rich plasma, PRP
Brief summary
Neurotrophic keratitis (NK) is a rare degenerative corneal disease caused by altered innervation of the trigeminal nerve that leads to rupture of the corneal epithelium, the regeneration deterioration and development of corneal ulceration, their fusion, and perforation The main characteristic in the NK is a decrease or absence of corneal sensitivity.
Detailed description
The goals of treatment in the neurotrophic keratitis are prevent the progression of corneal damage, maintain eye structure and improve the transparency of the cornea. Therapy should be initiated early and based on the clinical stage of the disease because it depends on epithelial state and in the degree of corneal hypoesthesia. Plasma rich in growth factors (PRGF-Endoret) represent a new technology using autologous proteins, growth factors and biomaterials as therapeutic formulations for different regenerative purposes. Under strict pharmaceutical development, it is possible to develop biologically stable eye drops, which have been shown to be useful for treating diverse ocular surface diseases. PRGF-Endoret eye drops could be an alternative therapy for patients with NK, and thus the objective of this clinical trial is to demonstrate its possible efficacy and its safety in patients with NK in stages 2 and 3.
Interventions
DRUGPRGF-Endoret
Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).
Sponsors
Biotechnology Institute IMASD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged 18 or over. * With neurotrophic keratitis at stages 2 or 3 affecting only one eye. * Persistent epithelial defect or corneal ulcer of at least 2 weeks duration resistant to one or more traditional non-surgical treatments . * Corneal sensitivity reduction test in the area of the persistent epithelial defect or corneal ulcer and out of the defect area in at least one corneal quadrant. * No objective clinical evidence of improvement in the two weeks prior to enrollment. * Patients who have previously read and signed the informed consent.
Exclusion criteria
* Patients with neurotrophic keratitis stages 2 or 3 that affects both eyes. * With active ocular infection or inflammation not related to the neurotrophic keratitis * Any other eye disease that requires of topical ocular treatment in the affected eye during study. * Patients with severe vision loss * Patients with severe blepharitis and/or severe Meibomian glands disease * History of eye surgery in the three months prior to enter the study, or patients who plan to undergo surgery. * Having received previously surgical procedures for the treatment of NK. * Use of therapeutic contact lenses or for refractive correction during study. * Patients with punctual occlusion or insertion of punctual plugs previous to the study * Evidence of corneal ulcer affecting the corneal stroma or cornea perforation. * Presence of any disorder or ocular or systemic disease that could limit the treatment effectiveness or its evaluation, * Any need of change (at that time or planned) in the dose of systemic drugs known to disrupt the functioning of the trigeminal nerve * Known hypersensitivity to any of the procedural compounds (eg. fluoresceine). * Presence of blood disorders associated with platelet disorders or clotting, or receiving anticoagulants drugs or antiplatelet agents. * Patients with positive result in one of the serological tests for syphilis, Hepatitis B-C or AIDS I / II. * Patient in current treatment for their pathology already well managed. * Use of any investigational drug within 4 weeks prior to the screening visit. * Pregnant women or intended to be pregnant. * Participating in another clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with a reduction of corneal defect of >50% | 4 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients showing complete healing of the corneal defect | 4 weeks | — |
| Measurement of the depth of the corneal defect (mm) | 2 and 4 weeks | — |
| Changes in percentage in Best corrected visual acuity (BCVA LogMAR) | 2 and 4 weeks | — |
| Percentage of patients with a reduction of corneal defect of >50% | 2 weeks | — |
| Osmolarity of lacrimal film | 2 and 4 weeks | — |
| Measurement of treatment tolerance | 2 and 4 weeks | Measurement of treatment tolerance with a 0 4 score |
| Adverse events | 2 and 4 weeks | Percentage of adverse event occurrence |
| Ocular pain with VAS scale | 2 and 4 weeks | — |
Countries
Spain
Outcome results
None listed